Research Grade Tebentafusp
Tebentafusp是新型双特异性蛋白，由与抗CD3免疫效应功能融合的可溶性T细胞受体组成。Tebentafusp特异性靶向gp100（一种在黑色素细胞和黑色素瘤中表达的谱系抗原），旨在重定向和激活T细胞，以识别和杀死肿瘤细胞。
货号:DHC27706
产品链接：http://www.atagenix.com/product_detail-75404.html
产品购买联系方式：027-65279366
产品介绍：Tebentafusp (IMCgp100)是一种双特异性融合蛋白，靶向gp100 (一种黑色素瘤相关抗原)。Tebentafusp通过高亲和力T细胞受体(TCR)结合域和抗CD3 T细胞接合域引导T细胞杀死表达gp100的肿瘤细胞。Tebentafusp诱导炎性细胞因子和细胞溶解蛋白的产生，导致肿瘤细胞的直接裂解。
通用名:Tebentafusp
纯度:>95% by SDS-PAGE.
浓度:1mg/ml
Formulationicon:0.01M PBS, pH 7.4.
内毒素:Please contact with the lab for this information.
别名:Bispecific fusion protein
靶点;物种:Human CD3E & TCR
种类:Humanized
受体鉴定:scFv-TR-BETA
CAS: 1874157-95-5
参考文献：
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. PMID: 35060440
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. PMID: 35254876
Antibodies to watch in 2022. PMID: 35030985
Tebentafusp for uveal melanoma. PMID: 34625736
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. PMID: 36970111
Uveal melanoma. PMID: 32273508
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. PMID: 36847626
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma. PMID: 36199496
Tebentafusp in first-line melanoma trials: An outperforming outlier. PMID: 35364557
Antibodies to watch in 2023. PMID: 36472472
Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations. PMID: 36785760
Metastatic uveal melanoma: The final frontier. PMID: 34999237
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. PMID: 35880455
Tebentafusp als neuartige Immuntherapie zeigt einen Überlebensvorteil beim metastasierten Uveamelanom und wird bereits in Deutschland eingesetzt. PMID: 35304951
A review of the cutaneous toxicities of tebentafusp-Featuring two cases involving superficial bullous reactions. PMID: 35510367
Advances in the clinical management of uveal melanoma. PMID: 36600005
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. PMID: 36931146
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. PMID: 37286303
Recent Advances and Challenges in Uveal Melanoma Immunotherapy. PMID: 35804863
Drug-induced photosensitivity during tebentafusp treatment for metastatic uveal melanoma: A newly described occurrence. PMID: 36177547
[New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients]. PMID: 36357199
Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. PMID: 34885078
Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report. PMID: 37207136
Review of bi-specific therapies in uveal melanoma. PMID: 35236927
Evolving Management of Stage IV Melanoma. PMID: 37141553
TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma. PMID: 35267523
First Drug Approved for Rare Eye Cancer. PMID: 35115315
Immunotherapies for the Treatment of Uveal Melanoma-History and Future. PMID: 31344957
Novel Approaches to the Systemic Management of Uveal Melanoma. PMID: 32725406
Combination strategies to durably suppress HIV-1: Soluble T cell receptors. PMID: 36065296
T cell engagers in solid tumors kick the door down. PMID: 34752755
Ensuring equity in the era of HLA-restricted cancer therapeutics. PMID: 36442912
Nail Apparatus Melanoma: Current Management and Future Perspectives. PMID: 36983205
TCR Bispecific Boosts Survival in Uveal Melanoma. PMID: 33839690
Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours. PMID: 31207478
Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis. PMID: 36094043
Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives. PMID: 34431316
Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. PMID: 36710368
Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors. PMID: 36255733
Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients. PMID: 36672442
Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review. PMID: 37350009
Immunotherapy for ocular melanoma: a bibliometric and visualization analysis from 1991 to 2022. PMID: 37324010
Determinants of overall survival in patients with metastatic uveal melanoma. PMID: 37382208
黑色素瘤是皮肤癌中最严重的一种，发生于产生黑色素（赋予肤色的色素）的细胞（黑色素细胞）中。黑色素瘤也可能在您的眼睛中形成，罕见情况下可在您的身体内部形成，如在鼻或咽喉。
所有黑色素瘤的确切病因尚不清楚，但暴露于阳光或日光浴灯和日光浴床的紫外线（UV）辐射会增加患黑色素瘤的风险。限制 UV 照射有助于降低患黑色素瘤的风险。
40 岁以下的人，尤其是女性，患黑色素瘤的风险似乎正在升高。了解皮肤癌的预警信号，有助于确保在癌症扩散之前发现癌变并进行治疗。如果在早期发现，黑色素瘤是可以成功治疗的。
黑色素瘤可能出现在您身体的任何部位。最常发生在阳光照射的部位，如背部、腿部、手臂和面部。
黑色素瘤也可能发生在阳光照射不多的区域，如脚底、手掌和指甲床。这些隐藏的黑色素瘤在肤色较深的人中更常见。
黑色素瘤的首发体征和症状通常为：
现有痣的改变
皮肤上出现新的色素沉着或外观异常的生长物
黑色素瘤并不总是以痣开始。也可发生在其他外观正常的皮肤上。
